Search

Your search keyword '"Portlock CS"' showing total 126 results

Search Constraints

Start Over You searched for: Author "Portlock CS" Remove constraint Author: "Portlock CS"
126 results on '"Portlock CS"'

Search Results

2. Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults

5. The Non-Hodgkin's Lymphomas: Current Concepts and Management

7. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial

8. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.

11. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.

12. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.

13. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

14. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

15. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.

16. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

17. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

18. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

19. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.

20. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

21. A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

22. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.

23. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.

24. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

25. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective.

26. Long-term cardiac and pulmonary complications of cancer therapy.

27. Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center.

28. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

29. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

30. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

31. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.

32. Long-term cardiac and pulmonary complications of cancer therapy.

33. Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.

34. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

39. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?

41. Variable problems in lymphomas: CASE 2. Sarcoidosis mimicking progressive lymphoma.

42. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.

44. Review.

45. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.

46. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.

49. The diminishing role of surgery in the treatment of gastric lymphoma.

50. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease.

Catalog

Books, media, physical & digital resources